BioPorto Diagnostics


DKK586.1m market cap

DKK3.35 last close

BioPorto is a diagnostic company focused on the development and marketing antibodies and other products for research and diagnostics. This includes products marketed for research use and The NGAL Test for the prediction of kidney failure.

Investment summary

BioPorto announced the decision to supplement its 510(k) paediatric application with additional data, rather than withdraw it. The FDA’s decision relating to The NGAL Test’s use in the risk assessment of acute kidney injury (AKI) in paediatric populations is expected by year end. In addition, the adult AKI programme is on track with expected FDA submission by year end. Our valuation is DKK993m (DKK5.67 per basic share).

Y/E Dec
Revenue (DKKm)
EPS (ore)
P/E (x)
P/CF (x)
2017A 25.2 (33.1) (34.2) (20.59) N/A N/A
2018A 26.0 (42.1) (42.5) (24.34) N/A N/A
2019E 31.5 (60.8) (62.3) (32.13) N/A N/A
2020E 53.7 (54.5) (54.7) (26.86) N/A N/A
Industry outlook

The current standard of care for detecting AKI is serum creatinine, which can take 24 hours or more to detect AKI and can only do so after significant kidney damage. NGAL promises to provide a quicker and more reliable test, allowing early intervention to preserve kidney function.

Last updated on 15/11/2019
Share price graph
Balance sheet
Forecast net cash (DKKm) 20.3
Forecast gearing ratio (%) N/A
Price performance
Actual 22.3 25.9 (13.3)
Relative* 14.5 13.4 (27.9)
52-week high/low DKK4.1/DKK2.6
*% relative to local index
Key management
Thomas Magnussen Chairman
Peter Mørch Eriksen CEO
Ole Larsen CFO
Jan Kuhlmann Andersen COO